BR0215029A - Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus - Google Patents

Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus

Info

Publication number
BR0215029A
BR0215029A BR0215029-8A BR0215029A BR0215029A BR 0215029 A BR0215029 A BR 0215029A BR 0215029 A BR0215029 A BR 0215029A BR 0215029 A BR0215029 A BR 0215029A
Authority
BR
Brazil
Prior art keywords
insulin molecule
preparing
diabetes mellitus
treating
composition
Prior art date
Application number
BR0215029-8A
Other languages
English (en)
Portuguese (pt)
Inventor
John Michael Beals
Michael Rosario Defelippis
Richard Dennis Dimarchi
Wayne David Kohn
Radmila Micanovic
Sharon Ruth Myers
Kingman Ng
Lianshan Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0215029A publication Critical patent/BR0215029A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0215029-8A 2001-12-20 2002-12-12 Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus BR0215029A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34431001P 2001-12-20 2001-12-20
US41460402P 2002-09-27 2002-09-27
PCT/US2002/037601 WO2003053339A2 (en) 2001-12-20 2002-12-12 Insulin molecule having protracted time action

Publications (1)

Publication Number Publication Date
BR0215029A true BR0215029A (pt) 2005-12-20

Family

ID=26993857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215029-8A BR0215029A (pt) 2001-12-20 2002-12-12 Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus

Country Status (17)

Country Link
US (1) US20050014679A1 (https=)
EP (1) EP1545460A4 (https=)
JP (1) JP2005519041A (https=)
KR (1) KR20040070237A (https=)
AU (1) AU2002346490A1 (https=)
BR (1) BR0215029A (https=)
CA (1) CA2468100A1 (https=)
CO (1) CO5590884A2 (https=)
CZ (1) CZ2004710A3 (https=)
HR (1) HRP20040551A2 (https=)
HU (1) HUP0700126A2 (https=)
IL (1) IL161848A0 (https=)
MX (1) MXPA04006084A (https=)
NO (1) NO20042172L (https=)
PL (1) PL374949A1 (https=)
SK (1) SK2432004A3 (https=)
WO (1) WO2003053339A2 (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452044A1 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
AU2004269196B2 (en) * 2003-09-03 2010-03-04 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
US7884181B2 (en) * 2004-10-05 2011-02-08 Novo Nordisk A/S Pharmaceutical formulation comprising crystalline insulin and dissolved insulin
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
ES2542146T3 (es) * 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
EP2229406B1 (de) * 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
RU2010147076A (ru) * 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
AU2013237740B2 (en) * 2008-07-31 2016-06-02 Case Western Reserve University Insulin analogues containing penta-fluora-phenyalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
WO2010080609A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN102307584A (zh) * 2008-12-19 2012-01-04 印第安纳大学研究及科技有限公司 表现出对胰岛素受体的高活性的基于yl的胰岛素-样生长因子
CN102300580A (zh) * 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EP2464655B1 (en) * 2009-08-11 2017-02-15 Biocon Limited Chromatographic processes
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
JP5119232B2 (ja) * 2009-11-06 2013-01-16 株式会社マルハニチロ食品 プロタミンの定量法
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
EA201200717A1 (ru) * 2009-12-11 2013-03-29 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP5912112B2 (ja) * 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
PH12012502472A1 (en) 2010-06-24 2013-03-25 Zealand Pharma As Glucagon analogues
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
EP2686003A2 (en) * 2011-03-15 2014-01-22 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP5950477B2 (ja) 2011-08-10 2016-07-13 アドシア 少なくとも１種の基礎インスリンの注射溶液
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
WO2013104861A1 (fr) 2012-01-09 2013-07-18 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
CA2898730A1 (en) * 2012-01-20 2013-07-25 Case Western Reserve University Glutamic acid-stabilized insulin analogues
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
WO2016049174A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Lipidated amide-based insulin prodrugs
AU2015328222B9 (en) 2014-10-06 2020-12-24 Case Western Reserve University Biphasic single-chain insulin analogues
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
KR20180002062U (ko) 2016-12-28 2018-07-06 유애자 크리스탈이 구비된 조명커버
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MA51127A (fr) 2017-12-07 2021-03-17 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
KR20240171196A (ko) 2017-12-07 2024-12-06 아도시아 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
TW224471B (https=) * 1991-11-26 1994-06-01 Lilly Co Eli
DK0622376T3 (da) * 1993-04-27 2001-11-12 Hoechst Ag Amorfe monosfæriske former af insulinderivater
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5491269A (en) * 1994-09-15 1996-02-13 Exxon Production Research Company Method for inhibiting hydrate formation
US5491296A (en) * 1994-12-05 1996-02-13 Holden's Foundation Seeds, Inc. Inbred corn line LH176
EA200000453A1 (ru) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Also Published As

Publication number Publication date
NO20042172L (no) 2004-09-17
JP2005519041A (ja) 2005-06-30
CA2468100A1 (en) 2003-07-03
CZ2004710A3 (cs) 2005-02-16
US20050014679A1 (en) 2005-01-20
AU2002346490A1 (en) 2003-07-09
EP1545460A2 (en) 2005-06-29
KR20040070237A (ko) 2004-08-06
HRP20040551A2 (en) 2004-10-31
PL374949A1 (en) 2005-11-14
EP1545460A4 (en) 2005-11-16
MXPA04006084A (es) 2005-03-31
HUP0700126A2 (en) 2007-06-28
WO2003053339A2 (en) 2003-07-03
SK2432004A3 (sk) 2005-04-01
CO5590884A2 (es) 2005-12-30
WO2003053339A3 (en) 2005-04-14
IL161848A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
BR0215029A (pt) Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
BR0014767A (pt) Fibras de sementes de plantas e uso
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
BRPI0418702A (pt) composição para a liberação sustentada de polipetìdeo biologicamente ativo, método para tratar um paciente sofrendo de diabetes tipo 2, processo para preparar uma composição para a liberação sustentada de um polipeptìdeo, composição para a liberação sustentada de um agente biologicamente ativo, processo para preparar uma composição para a liberação sustentada de exendina-4, composição injetável, kit para produzir uma composição injetável, composição farmaceuticamente aceitável para a liberação sustentada de um polipeptìdeo biologicamente ativo e método para tratar um paciente sofrendo de diabetes mellitus
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
BR9911656A (pt) Composição farmacêutica, processos para prevenção ou tratamento de diabetes em um mamìfero, para prevenção ou tratamento de complicações diabéticas em um mamìfero e para prevenção ou tratamento da tolerância a glicose prejudicada em um mamìfero, uso de um sensibilizador de insulina, e, proceso para reduzir os efeitos colaterais de um sensibilizador de insulina ou/ e um anorético administrado a um mamìfero diabético
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
BRPI0111116B8 (pt) imitadores de trombopoietina
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BRPI0409600A (pt) análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
BR0107902A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, e para o tratamento e/ou prevençao de, condições mediadas por receptores nucleares, e diabetes e/ou obesidade, uso de uim composto, processo para a preparação de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glucose, resistência à insolina ou obesidade
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
BR0205062A (pt) Spandex e processo para produzir spandex
BRPI0417469B8 (pt) bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.